† Source: Managed Markets Insight & Technology, LLC,
database as of January 2026. Certain plans may require prior
authorization.
‡ This is not a guarantee of coverage or payment (partial
or full). Actual benefits are determined by each plan
administrator in accordance with its respective policy and
procedures. Nothing herein may be construed as an endorsement,
approval, recommendation, representation or warranty of any kind
by any plan or insurer referenced herein.
*Patient Co-Pay Eligibility, Terms, and Conditions
Eligible patients may pay a minimum of $0 and receive up to $2,000
off the patient's co-pay or out-of-pocket expenses per
prescription fill of PANCREAZE (pancrelipase) capsules with a
maximum yearly benefit of $3,500. Out-of-pocket expenses may vary.
Patient Instructions: In order to redeem the
offer, you must have a valid prescription for PANCREAZE. This
offer may not be redeemed for cash. By using this offer, you are
certifying that you meet the eligibility criteria and will comply
with the terms and conditions below.
Terms and conditions: Offer is not transferable.
Patients are not eligible if they are covered in whole or in part
by any state program or federal healthcare program, including, but
not limited to, Medicare or Medicaid (including Medicaid managed
care), Medigap, VA, DOD, or TRICARE. Only valid in the United
States, Puerto Rico, Guam and the U.S. Virgin Islands. Offer void
where prohibited by law, taxed, or restricted. Other restrictions
may apply. This program is not health insurance. VIVUS LLC has the
right to rescind, revoke, or amend this program at any time
without notice. Your participation in this program confirms that
this offer is consistent with your insurance coverage and that you
will report the value received if required by your insurance
provider. When you use this card, you are certifying that you
understand and will comply with the program rules, terms, and
conditions.
Indication
PANCREAZE is indicated for the treatment of exocrine pancreatic
insufficiency in adult and pediatric patients.
Important Safety Information
Fibrosing Colonopathy: Associated with high doses, usually over
prolonged use and in pediatric patients with cystic fibrosis.
Colonic stricture reported in pediatric patients less than 12
years of age with dosages exceeding 6,000 lipase units/kg/meal.
Monitor during treatment for progression of preexisting disease.
Do not exceed the recommended dosage, unless clinically indicated.
Hyperuricemia has been reported with high dosages; consider
monitoring blood uric acid levels in patients with gout, renal
impairment, or hyperuricemia.
Irritation of the oral mucosa may occur due to loss of protective
enteric coating on the capsule contents.
The presence of porcine viruses that might infect humans cannot be
definitely excluded.
Monitor patients with known reactions to proteins of porcine
origin. If symptoms occur, initiate appropriate medical
management; consider the risks and benefits of continued
treatment.
Please read the
PANCREAZE Medication Guide
and
PANCREAZE Product Information
and discuss any questions you have with your doctor.
References: 1. References: Trapnell BC,
Strausbaugh SD, Woo MS, et al. Efficacy and safety of PANCREAZE
for treatment of exocrine pancreatic insufficiency due to cystic
fibrosis. J Cyst Fibros. 2011;10(5):350-356.
2. Cystic Fibrosis Foundation. (n.d.).
Phthalates. Retrieved from https://www.cff.org/phthalates. 3.
PANCREAZE Full Prescribing Information. Campbell, CA: VIVUS LLC;
2024.
